drugset / Trial / NCT03828123
Autologous Multipotent Mesenchymal Stromal Cells in the Treatment of Amyotrophic Lateral Sclerosis
NaSingle-groupOpen-labelTreatment
Summary
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that targets motor neurons. Prognosis is invariably fatal within 3-5 years since manifestation of the disease. Despite improved understanding of the mechanisms underlying ALS, the treatment remains essentially only supportive and focused on symptoms relief. Over the past few years, stem cell research has expanded greatly as a tool for developing new therapies to treat incurable diseases. Stem cell therapy has been shown as promising in several animal ALS models and human clinical trials.
Timeline
- Start
- 2012-01
- Primary completion
- 2017-08-18
- Completion
- 2017-08-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous Multipotent Mesenchymal Stromal Cells | Unknown | 1.5 ml | Intrathecal |
| Subject | Autologous Multipotent Mesenchymal Stromal Cells | Unknown | 1.5e+07 cells | Intrathecal |